RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Alterity Therapeutics Stock

Alterity Therapeutics P/S 2024

Alterity Therapeutics P/S

68.5

Ticker

ATH.AX

ISIN

AU0000043945

WKN

A2PHDZ

As of Sep 26, 2024, Alterity Therapeutics's P/S ratio stood at 68.5, a 6,550.49% change from the 1.03 P/S ratio recorded in the previous year.

The Alterity Therapeutics P/S history

Alterity Therapeutics Aktienanalyse

What does Alterity Therapeutics do?

Alterity Therapeutics Ltd is an Australian company specializing in the discovery and development of therapeutics for neurodegenerative diseases. The company's history dates back to 1997 when it was established under the name Prana Biotechnology Limited. Alterity Therapeutics' business model is based on the research of protein aggregates responsible for neurodegenerative diseases. The company primarily focuses on developing drugs targeting the breakdown of these protein aggregates to minimize the effects of diseases such as Parkinson's, Alzheimer's, and Huntington's. The company has several divisions specializing in various aspects of product development, including preclinical research, clinical development, and commercial marketing. Alterity Therapeutics has several products in various stages of development. One of its leading products is PBT434, a drug that aims to prevent protein aggregates in the brain and target the treatment of Parkinson's disease. The drug has already been tested in clinical trials and has shown promising results. In addition to PBT434, the company also has other promising drugs in development, including PBT519, targeting the treatment of Alzheimer's disease, and PBT2, targeting the treatment of Huntington's disease. Alterity Therapeutics aims to minimize the impact of neurodegenerative diseases and improve the quality of life for millions of patients worldwide. The company collaborates with leading medical and academic institutions to develop innovative therapeutics that meet the needs of patients and clinicians. Overall, Alterity Therapeutics offers a promising pipeline of drugs that could play a significant role in the treatment of neurodegenerative diseases. The company has become a major player in the industry and has the potential to make a significant impact in the fight against these serious illnesses. Alterity Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Alterity Therapeutics's P/S Ratio

Alterity Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Alterity Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Alterity Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Alterity Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Alterity Therapeutics stock

What is the price-to-earnings ratio of Alterity Therapeutics?

The price-earnings ratio of Alterity Therapeutics is currently 68.5.

How has the price-earnings ratio of Alterity Therapeutics changed compared to last year?

The price-to-earnings ratio of Alterity Therapeutics has increased by 6,550.49% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Alterity Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Alterity Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Alterity Therapeutics affect the company?

An increase in the price-earnings ratio of Alterity Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Alterity Therapeutics affect the company?

A decrease in the price-earnings ratio of Alterity Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Alterity Therapeutics?

Some factors that influence the price-earnings ratio of Alterity Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Alterity Therapeutics pay?

Over the past 12 months, Alterity Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alterity Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Alterity Therapeutics?

The current dividend yield of Alterity Therapeutics is .

When does Alterity Therapeutics pay dividends?

Alterity Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alterity Therapeutics?

Alterity Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Alterity Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alterity Therapeutics located?

Alterity Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alterity Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alterity Therapeutics from 9/26/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

When did Alterity Therapeutics pay the last dividend?

The last dividend was paid out on 9/26/2024.

What was the dividend of Alterity Therapeutics in the year 2023?

In the year 2023, Alterity Therapeutics distributed 0 AUD as dividends.

In which currency does Alterity Therapeutics pay out the dividend?

The dividends of Alterity Therapeutics are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Alterity Therapeutics

Our stock analysis for Alterity Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alterity Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.